{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:43:53Z","timestamp":1785545033149,"version":"3.56.0"},"reference-count":54,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Cancer"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Focal high-intensity focused ultrasound (HIFU) is an emerging tissue-preserving treatment for localized prostate cancer (PCa) that aims to reduce functional impairment and psychological burden while maintaining oncological safety. Although its clinical use is increasing, prospective data on health-related quality of life (HRQoL) and psychological distress after focal hemiablation remain limited.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n This study aims to evaluate longitudinal HRQoL trajectories and psychological outcomes in patients eligible for active surveillance who underwent focal HIFU following shared decision-making.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This prospective, multicenter, single-arm longitudinal study included men with unilateral, organ-confined PCa treated with focal HIFU hemiablation within the HEMI study (AP study protocol\/reference number: 68\/11, AUO). All patients had concordant multiparametric magnetic resonance imaging and biopsy findings, and underwent standardized unilateral HIFU. HRQoL was assessed at baseline and at 1, 3, 6, 9, and 12 months using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire\u2014Core 30 (EORTC QLQ-C30, version 3.0). Psychological distress was measured with the Hospital Anxiety and Depression Scale. Longitudinal changes were analyzed using linear mixed-effects models with false discovery rate correction. In addition, univariate regression analyses were performed to assess associations between clinical and functional parameters, and HRQoL outcomes. Outcomes were compared with German and Norwegian normative populations, and clinical relevance was interpreted using Osoba criteria.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Fifty-four patients were included, of whom 51 (94.4%) completed 12-month follow-up (mean age 63.4, SD 8.3 y). Baseline HRQoL, functional status, and symptom burden were favorable. One month after hemi-HIFU, a statistically significant and clinically moderate decline in global health status was observed (mean 75 [SD 17.8] vs 63 [SD 17.9];\n P<\/jats:italic>\n =.002; Cohen\n d<\/jats:italic>\n =0.58). This transient deterioration was mainly driven by increased fatigue, pain, insomnia, appetite loss, and reduced physical, role, and social functioning, with social functioning most affected. Emotional and cognitive functioning remained stable. From 3 months onward, HRQoL and all functional domains recovered to baseline or higher levels, with no clinically relevant impairments at 12 months. Symptom burden normalized across most domains after 3 months, although mild constipation remained slightly elevated. Depression scores showed a transient increase at 1 and 3 months but remained below clinical thresholds, whereas anxiety scores were stable at all time points. In univariate regression analyses, no clinical or functional parameters were identified as independent predictors of HRQoL. Overall, recovery was rapid, long-term HRQoL was preserved, and treatment-related morbidity remained low.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Focal HIFU hemiablation preserves long-term HRQoL and psychological well-being in carefully selected patients with localized PCa. Early postoperative impairment is temporary, with recovery to baseline and convergence with normative population values from 3 months onward. Clinical and functional parameters were not significant predictors of HRQoL. These findings support focal HIFU as a minimally invasive quality-of-life\u2013preserving treatment option.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/91984","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T16:20:06Z","timestamp":1778775606000},"page":"e91984-e91984","source":"Crossref","is-referenced-by-count":0,"title":["Patient-Reported Outcomes on Quality of Life and Psychological Distress After Focal High-Intensity Focused Ultrasound for Prostate Cancer: Prospective Multicenter Study"],"prefix":"10.2196","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7184-1098","authenticated-orcid":false,"given":"Toni","family":"Franz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2842-263X","authenticated-orcid":false,"given":"Cornelia","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4590-5749","authenticated-orcid":false,"given":"Roman","family":"Ganzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9091-5244","authenticated-orcid":false,"given":"Sigrun","family":"Holze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5668-1056","authenticated-orcid":false,"given":"Jens-Uwe","family":"Stolzenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.811044","article-title":"Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019","volume":"10","author":"Wang","journal-title":"Front Public Health"},{"key":"R2","unstructured":"Cancer stat facts: prostate cancer. National Cancer Institute SEER. URL: https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html [Accessed 01-12-2025]"},{"key":"R3","unstructured":"European Cancer Information System. URL: https:\/\/ecis.jrc.ec.europa.eu [Accessed 01-12-2025]"},{"issue":"5","key":"R4","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1056\/NEJMoa1209978","article-title":"Long-term functional outcomes after treatment for localized prostate cancer","volume":"368","author":"Resnick","journal-title":"N Engl J Med"},{"issue":"12","key":"R5","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1056\/NEJMoa074311","article-title":"Quality of life and satisfaction with outcome among prostate-cancer survivors","volume":"358","author":"Sanda","journal-title":"N Engl J Med"},{"issue":"9","key":"R6","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.31557\/APJCP.2025.26.9.3185","article-title":"Quality of life in prostate cancer patients following radical prostatectomy: a systematic review and meta-analysis","volume":"26","author":"Seputra","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"R7","doi-asserted-by":"publisher","DOI":"10.1007\/s11701-025-02496-x","article-title":"Postoperative functional complications and quality of life following robot-assisted prostatectomy and radiotherapy in localized prostate cancer: evidence from a systematic review and meta-analysis","volume":"19","author":"Liu","journal-title":"J Robot Surg"},{"issue":"12","key":"R8","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1093\/jnci\/95.12.868","article-title":"Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer","volume":"95","author":"Draisma","journal-title":"J Natl Cancer Inst"},{"issue":"13","key":"R9","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","article-title":"Screening and prostate-cancer mortality in a randomized European study","volume":"360","author":"Schr\u00f6der","journal-title":"N Engl J Med"},{"issue":"19","key":"R10","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1056\/NEJMoa043739","article-title":"Radical prostatectomy versus watchful waiting in early prostate cancer","volume":"352","author":"Bill-Axelson","journal-title":"N Engl J Med"},{"issue":"32","key":"R11","doi-asserted-by":"publisher","first-page":"8165","DOI":"10.1200\/JCO.2005.03.3134","article-title":"Active surveillance for prostate cancer: for whom?","volume":"23","author":"Klotz","journal-title":"J Clin Oncol"},{"issue":"3 Pt 1","key":"R12","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.juro.2007.05.039","article-title":"The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance","volume":"178","author":"Latini","journal-title":"J Urol"},{"issue":"6","key":"R13","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1016\/j.juro.2009.08.044","article-title":"Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance","volume":"182","author":"Fujita","journal-title":"J Urol"},{"issue":"3 Pt 2","key":"R14","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/j.juro.2007.03.135","article-title":"Contemporary trends in low risk prostate cancer: risk assessment and treatment","volume":"178","author":"Cooperberg","journal-title":"J Urol"},{"issue":"1","key":"R15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2016.08.044","article-title":"New and established technology in focal ablation of the prostate: a systematic review","volume":"71","author":"Valerio","journal-title":"Eur Urol"},{"issue":"49","key":"R16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta19490","article-title":"Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation","volume":"19","author":"Ramsay","journal-title":"Health Technol Assess"},{"issue":"2","key":"R17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1470-2045(16)30661-1","article-title":"Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial","volume":"18","author":"Azzouzi","journal-title":"Lancet Oncol"},{"issue":"6","key":"R18","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.eururo.2007.10.062","article-title":"First analysis of the long-term results with transrectal HIFU in patients with localised prostate cancer","volume":"53","author":"Blana","journal-title":"Eur Urol"},{"issue":"5","key":"R19","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.urology.2007.12.076","article-title":"Factors predicting for formation of bladder outlet obstruction after high-intensity focused ultrasound in treatment of localized prostate cancer","volume":"71","author":"Blana","journal-title":"Urology"},{"issue":"3","key":"R20","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/j.1464-410X.2012.11715.x","article-title":"Fourteen-year oncological and functional outcomes of high-intensity focused ultrasound in localized prostate cancer","volume":"112","author":"Ganzer","journal-title":"BJU Int"},{"issue":"2","key":"R21","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.eururo.2016.09.039","article-title":"Focal high intensity focused ultrasound of unilateral localized prostate cancer: a prospective multicentric hemiablation study of 111 patients","volume":"71","author":"Rischmann","journal-title":"Eur Urol"},{"issue":"1","key":"R22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/pcan.2015.55","article-title":"A prospective clinical trial of HIFU hemiablation for clinically localized prostate cancer","volume":"19","author":"van Velthoven","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"R23","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.eururo.2015.06.018","article-title":"Focal high-intensity focused ultrasound targeted hemiablation for unilateral prostate cancer: a prospective evaluation of oncologic and functional outcomes","volume":"69","author":"Feijoo","journal-title":"Eur Urol"},{"issue":"4","key":"R24","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.juro.2010.11.079","article-title":"Focal therapy for localized prostate cancer: a phase I\/II trial","volume":"185","author":"Ahmed","journal-title":"J Urol"},{"issue":"6","key":"R25","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.eururo.2015.01.013","article-title":"Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature","volume":"68","author":"F\u00fctterer","journal-title":"Eur Urol"},{"issue":"4","key":"R26","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1001\/jama.2014.17942","article-title":"Comparison of MR\/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer","volume":"313","author":"Siddiqui","journal-title":"JAMA"},{"issue":"5","key":"R27","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.eururo.2012.01.047","article-title":"Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers","volume":"62","author":"Hoeks","journal-title":"Eur Urol"},{"issue":"4","key":"R28","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.juro.2011.05.078","article-title":"Magnetic resonance imaging\/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging","volume":"186","author":"Pinto","journal-title":"J Urol"},{"issue":"4","key":"R29","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.eururo.2010.12.009","article-title":"Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting","volume":"59","author":"Dickinson","journal-title":"Eur Urol"},{"key":"R30","unstructured":"Glatzer W Zapf W . Lebensqualit\u00e4t in Der Bundesrepublik: Objektive Lebensbedingungen Und Subjektives Wohlbefinden [Book in German]. Campus Verlag; 1984. ISBN: 3-593-33243-4"},{"key":"R31","unstructured":"Buddeberg C . Psychosoziale Medizin. 3rd ed. Springer; 2003. ISBN: 3-540-00875-6"},{"issue":"10","key":"R32","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/0277-9536(95)00112-K","article-title":"The World Health Organization quality of life assessment (WHOQOL): position paper from the World Health Organization","volume":"41","author":"The WHOQOL Group","journal-title":"Soc Sci Med"},{"issue":"9","key":"R33","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1007\/s00120-024-02405-4","article-title":"Patient-reported outcomes\u2014the role of the patient\u2019s subjective perspective for research and clinical care","volume":"63","author":"Dinkel","journal-title":"Urologie"},{"issue":"10","key":"R34","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1007\/s11136-019-02214-9","article-title":"A systematic review of quality of life research in medicine and health sciences","volume":"28","author":"Haraldstad","journal-title":"Qual Life Res"},{"issue":"2","key":"R35","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s11136-024-03820-y","article-title":"Exploring the role of health-related quality of life measures in predictive modelling for oncology: a systematic review","volume":"34","author":"van der Heijden","journal-title":"Qual Life Res"},{"issue":"9","key":"R36","doi-asserted-by":"publisher","first-page":"e499","DOI":"10.1016\/S1470-2045(25)00288-8","article-title":"Importance of responder criteria for reporting health-related quality-of-life data in clinical trials for advanced cancer: recommendations of Common Sense Oncology and the European Organisation for Research and Treatment of Cancer","volume":"26","author":"Tannock","journal-title":"Lancet Oncol"},{"issue":"5","key":"R37","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1097\/01.ju.0000061964.49961.55","article-title":"Health related quality of life in men with prostate cancer","volume":"169","author":"Penson","journal-title":"J Urol"},{"issue":"4","key":"R38","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.juro.2017.10.033","article-title":"Prospective multicenter phase II study on focal therapy (hemiablation) of the prostate with high intensity focused ultrasound","volume":"199","author":"Ganzer","journal-title":"J Urol"},{"issue":"2","key":"R39","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","journal-title":"Eur Urol"},{"issue":"5","key":"R40","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","journal-title":"J Natl Cancer Inst"},{"key":"R41","unstructured":"The EORTC QLQ-C30 scoring manual. European Organisation for Research and Treatment of Cancer; 2001. URL: https:\/\/www.eortc.org\/app\/uploads\/sites\/2\/2018\/02\/SCmanual.pdf [Accessed 27-05-2026]"},{"issue":"11","key":"R42","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/s0959-8049(00)00447-0","article-title":"Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population","volume":"37","author":"Schwarz","journal-title":"Eur J Cancer"},{"issue":"3","key":"R43","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1200\/JCO.1998.16.3.1188","article-title":"Health-related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire: the QLQ-C30 (+ 3)","volume":"16","author":"Hjermstad","journal-title":"J Clin Oncol"},{"issue":"1","key":"R44","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","journal-title":"J Clin Oncol"},{"key":"R45","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-1-29","article-title":"The Hospital Anxiety and Depression Scale","volume":"1","author":"Snaith","journal-title":"Health Qual Life Outcomes"},{"key":"R46","volume":"40","author":"Herrmann","journal-title":"Diagnostica"},{"key":"R47","unstructured":"Herrmann-Lingen C Buss U Snaith RP . Hospital Anxiety and Depression Scale \u2013 Deutsche Version [German Version] Deutsche Adaptation Der Hospital Anxiety and Depression Scale (HADS) von R P Snaith Und A S Zigmond. 3rd ed. Verlag Hans Huber; 2011."},{"issue":"1","key":"R48","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.eururo.2021.08.005","article-title":"An updated systematic review on focal therapy in localized prostate cancer: what has changed over the past 5 years?","volume":"81","author":"Hopstaken","journal-title":"Eur Urol"},{"issue":"13","key":"R49","doi-asserted-by":"publisher","DOI":"10.21037\/atm-22-50","article-title":"Focal therapy for prostate cancer: what is really needed to move from investigational to valid therapeutic alternative? A narrative review","volume":"10","author":"Pellegrino","journal-title":"Ann Transl Med"},{"issue":"3","key":"R50","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/s41391-024-00921-0","article-title":"Focal therapy using high-intensity focused ultrasound with intraoperative prostate compression for patients with localized prostate cancer: a multi-center prospective study with 7 year experience","volume":"28","author":"Shoji","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"R51","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00345-018-2364-x","article-title":"Ablation energies for focal treatment of prostate cancer","volume":"37","author":"Lodeizen","journal-title":"World J Urol"},{"issue":"9","key":"R52","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1089\/end.2018.0130","article-title":"Focal treatment for unilateral prostate cancer using high-intensity focal ultrasound: a comprehensive study of pooled data","volume":"32","author":"Albisinni","journal-title":"J Endourol"},{"issue":"5","key":"R53","doi-asserted-by":"publisher","first-page":"268","DOI":"10.5152\/dir.2018.17374","article-title":"Impact on genitourinary function and quality of life following focal irreversible electroporation of different prostate segments","volume":"24","author":"Scheltema","journal-title":"Diagn Interv Radiol"},{"issue":"9","key":"R54","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1159\/000520084","article-title":"Decision regret and quality of life after focal therapy with vascular-targeted photodynamic therapy (TOOKAD\u00ae) for localized prostate cancer","volume":"106","author":"Flegar","journal-title":"Urol Int"}],"container-title":["JMIR Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cancer.jmir.org\/2026\/1\/e91984","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:24:02Z","timestamp":1785536642000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancer.jmir.org\/2026\/1\/e91984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":54,"URL":"https:\/\/doi.org\/10.2196\/91984","relation":{},"ISSN":["2369-1999"],"issn-type":[{"value":"2369-1999","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"article-number":"v12i5e91984"}}